46 explore the feasibility of using CRISPR-Cas9 gene editing technology to repair melanocyte functional defects, thereby advancing vitiligo treatment from symptom control to targeting root causes
This cardiovascular outcomes trial of semaglutide versus placebo in patients with type 2 diabetes at high cardiovascular risk revealed an unexpected finding: patients receiving semaglutide experienced a statistically significant increase in diabetic retinopathy complications (hazard ratio 1.76, 95% CI 1.112.78, p=0.02)
For the study, researchers tracked 1,070 kids aged 12 to 18 who were overweight or obese and also had a diagnosis of asthma
She also says semaglutides may be a good option for those with cardiovascular disease, according to research
Catch #4: The $50 hides a few things Without insurance, these drugs run roughly $900 to $1,400 a month, so $50 looks like a rounding error